JP2010516707A - ペプチド組成物の安定性および送達効率を上昇させるための修飾方法 - Google Patents

ペプチド組成物の安定性および送達効率を上昇させるための修飾方法 Download PDF

Info

Publication number
JP2010516707A
JP2010516707A JP2009546577A JP2009546577A JP2010516707A JP 2010516707 A JP2010516707 A JP 2010516707A JP 2009546577 A JP2009546577 A JP 2009546577A JP 2009546577 A JP2009546577 A JP 2009546577A JP 2010516707 A JP2010516707 A JP 2010516707A
Authority
JP
Japan
Prior art keywords
peptide
composition
cargo
carrier
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2009546577A
Other languages
English (en)
Japanese (ja)
Inventor
デレク マクレーン
Original Assignee
カイ ファーマシューティカルズ インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カイ ファーマシューティカルズ インコーポレーティッド filed Critical カイ ファーマシューティカルズ インコーポレーティッド
Publication of JP2010516707A publication Critical patent/JP2010516707A/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11013—Protein kinase C (2.7.11.13)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2009546577A 2007-01-19 2008-01-22 ペプチド組成物の安定性および送達効率を上昇させるための修飾方法 Ceased JP2010516707A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88141907P 2007-01-19 2007-01-19
US94528507P 2007-06-20 2007-06-20
PCT/US2008/051706 WO2008089491A2 (en) 2007-01-19 2008-01-22 Modifications of peptide compositions to increase stability and delivery efficiency

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014143781A Division JP5937643B2 (ja) 2007-01-19 2014-07-14 ペプチド組成物の安定性および送達効率を上昇させるための修飾方法

Publications (1)

Publication Number Publication Date
JP2010516707A true JP2010516707A (ja) 2010-05-20

Family

ID=39636771

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2009546577A Ceased JP2010516707A (ja) 2007-01-19 2008-01-22 ペプチド組成物の安定性および送達効率を上昇させるための修飾方法
JP2014143781A Active JP5937643B2 (ja) 2007-01-19 2014-07-14 ペプチド組成物の安定性および送達効率を上昇させるための修飾方法
JP2016096016A Pending JP2016147905A (ja) 2007-01-19 2016-05-12 ペプチド組成物の安定性および送達効率を上昇させるための修飾方法
JP2018058012A Pending JP2018111717A (ja) 2007-01-19 2018-03-26 ペプチド組成物の安定性および送達効率を上昇させるための修飾方法
JP2021036134A Pending JP2021098725A (ja) 2007-01-19 2021-03-08 ペプチド組成物の安定性および送達効率を上昇させるための修飾方法
JP2023049966A Pending JP2023078424A (ja) 2007-01-19 2023-03-27 ペプチド組成物の安定性および送達効率を上昇させるための修飾方法
JP2025170793A Pending JP2025185093A (ja) 2007-01-19 2025-10-09 ペプチド組成物の安定性および送達効率を上昇させるための修飾方法

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2014143781A Active JP5937643B2 (ja) 2007-01-19 2014-07-14 ペプチド組成物の安定性および送達効率を上昇させるための修飾方法
JP2016096016A Pending JP2016147905A (ja) 2007-01-19 2016-05-12 ペプチド組成物の安定性および送達効率を上昇させるための修飾方法
JP2018058012A Pending JP2018111717A (ja) 2007-01-19 2018-03-26 ペプチド組成物の安定性および送達効率を上昇させるための修飾方法
JP2021036134A Pending JP2021098725A (ja) 2007-01-19 2021-03-08 ペプチド組成物の安定性および送達効率を上昇させるための修飾方法
JP2023049966A Pending JP2023078424A (ja) 2007-01-19 2023-03-27 ペプチド組成物の安定性および送達効率を上昇させるための修飾方法
JP2025170793A Pending JP2025185093A (ja) 2007-01-19 2025-10-09 ペプチド組成物の安定性および送達効率を上昇させるための修飾方法

Country Status (8)

Country Link
US (7) US8067532B2 (https=)
EP (2) EP2109619B1 (https=)
JP (7) JP2010516707A (https=)
KR (4) KR102274003B1 (https=)
CN (3) CN101675067B (https=)
AU (1) AU2008206077A1 (https=)
CA (2) CA2989778C (https=)
WO (1) WO2008089491A2 (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2822302A1 (en) * 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Methods of impairing osteoclast differentiation
US8168181B2 (en) * 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
JP5645408B2 (ja) 2006-11-16 2014-12-24 カイ ファーマシューティカルズ インコーポレーティッド 副甲状腺機能亢進症および高カルシウム血症性障害の治療のためのポリカチオン性カルシウムモジュレーターペプチド
CA2989778C (en) 2007-01-19 2020-06-30 Kai Pharmaceuticals, Inc. Method of modifying peptide compositions
US20090318351A1 (en) * 2008-03-12 2009-12-24 Kevin Grimes Method of treating acute st-elevation myocardial infarction with a delta pkc antagonist
US20100311671A1 (en) * 2009-03-25 2010-12-09 Kai Pharmaceuticals Transdermal delivery of pkc modulatory peptides through microporated skin
US8999932B2 (en) 2009-07-29 2015-04-07 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
HRP20161566T1 (hr) 2011-06-08 2017-02-24 Kai Pharmaceuticals, Inc. Terapijski agensi za reguliranje serumskog fosfora
US20150038435A1 (en) * 2012-03-01 2015-02-05 Novo Nordisk A/S N-terminally modified oligopeptides and uses thereof
HK1210192A1 (en) 2012-07-19 2016-04-15 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
MX2015014438A (es) 2013-04-18 2016-05-18 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
EP3010527B1 (en) 2013-06-17 2018-08-08 Armo Biosciences, Inc. Method for assessing protein identity and stability
MA38724B1 (fr) * 2013-06-28 2017-11-30 Amgen Inc Formulation liquide stable d'amg 416 (velcalcétide)
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
CA2927592C (en) 2013-10-28 2020-08-18 Ngm Biopharmaceuticals, Inc. Fgf-19 variants for treating a fgf-19 dependent cancer or tumor
CN120242030A (zh) 2013-11-11 2025-07-04 阿尔莫生物科技股份有限公司 将白细胞介素-10用于治疗疾病和病症的方法
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
WO2016060996A2 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10456475B2 (en) 2015-02-03 2019-10-29 Kennsaw State University Research and Service Foundation, Inc. Cell penetrating protein adaptor molecules and their application in research and medicine
US20160361415A1 (en) 2015-05-28 2016-12-15 Armo Biosciences, Inc. Methods of Using Interleukin-10 for Treating Diseases and Disorders
HK1245671A1 (zh) 2015-05-29 2018-08-31 Armo Biosciences, Inc. 使用白细胞介素-10治疗疾病和病症的方法
US10435446B2 (en) 2015-06-03 2019-10-08 Kennesaw State University Research and Service Foundation Inc. Cell penetrating protein adaptor molecules and their application in research and medicine
KR20180038553A (ko) 2015-08-25 2018-04-16 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
US10981957B2 (en) * 2015-12-02 2021-04-20 Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement Peptides having antimicrobial activity and new enzyme capable of converting L-configured residue in D-configured amino acid in a peptide
US10654894B2 (en) 2016-02-03 2020-05-19 Keenesaw State University Research And Service Foundation, Inc. Methods for delivering cargo into a cell by using signal molecules as cell penetration agents
US11246905B2 (en) 2016-08-15 2022-02-15 President And Fellows Of Harvard College Treating infections using IdsD from Proteus mirabilis
KR101772449B1 (ko) 2016-12-27 2017-08-30 주식회사 하이센스바이오 신규한 펩타이드
US12410143B2 (en) 2017-01-17 2025-09-09 Michael David FORREST Therapeutic inhibitors of the reverse mode of ATP synthase
BR112019028172A2 (pt) 2017-07-13 2020-10-06 Michael David Forrest moduladores terapêuticos do modo reverso da atp sintase
US20200353050A1 (en) 2017-11-10 2020-11-12 Armo Biosciences, Inc. Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitors
US20210330738A1 (en) * 2018-03-29 2021-10-28 Contrafect Corporation Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria
WO2019245817A1 (en) 2018-06-19 2019-12-26 Armo Biosciences, Inc. Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy
US10905738B2 (en) * 2018-07-05 2021-02-02 Biozeus Desenvolvimento De Produtos Biofarmacêuticos Synthetic peptides, prodrugs, pharmaceutical compositions and uses
GB201903873D0 (en) * 2019-03-21 2019-05-08 Univ Nottingham Enhanced transfection
CN114096554A (zh) 2019-07-02 2022-02-25 Ａｇｃ株式会社 肽及其制造方法
JP7725466B2 (ja) 2019-11-13 2025-08-19 アムニクス ファーマシューティカルズ， インコーポレイテッド バーコード化されたｘｔｅｎポリペプチドおよびその組成物、ならびにその作製および使用方法
US20230125482A1 (en) * 2020-03-24 2023-04-27 Young Therapeutics, Llc Protein kinase c modulators
MX2023007788A (es) 2021-01-24 2023-11-17 Michael David Forrest Inhibidores de la atp sintasa, usos cosmeticos y terapeuticos.
EP4406961A4 (en) 2021-09-22 2025-11-05 Agc Inc PEPTIDE
KR102380732B1 (ko) 2021-09-23 2022-04-04 엘이솔루션 주식회사 축산분뇨처리시스템
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002502376A (ja) * 1997-05-21 2002-01-22 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ 生物学的膜を横切る輸送を増強するための組成物および方法
US20020150984A1 (en) * 2001-01-18 2002-10-17 Daria Mochly-Rosen Peptides for activation and inhibition of deltaPKC
JP2005500002A (ja) * 2000-10-02 2005-01-06 エリゼク・ファーマシュウティカルズ・インコーポレイテッド 生物学的に活性な薬剤を細胞関門を越えて輸送するための組成物および方法
JP2005523326A (ja) * 2002-04-22 2005-08-04 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ プロテインキナーゼｃのペプチドインヒビター
JP2006501165A (ja) * 2002-06-07 2006-01-12 ユニバーシティ オブ ローザンヌ Ｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US615977A (en) * 1898-12-13 Car-fender
US6316003B1 (en) 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5783405A (en) 1994-02-01 1998-07-21 Terrapin Technologies, Inc. Rapid screening method for effectors of signal transduction
US5935803A (en) * 1994-02-01 1999-08-10 Terrapin Technologies, Inc. Methods to identify immunomodulators using cognate interaction of PKC-theta
US5776716A (en) * 1994-02-01 1998-07-07 Terrapin Technologies, Inc. Methods for identifying agents which block the interaction of fyn with PKC-theta, and uses thereof
WO1998017299A1 (en) 1996-10-18 1998-04-30 The Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific activators of protein kinase c, methods and compositions
AU741546B2 (en) 1997-07-24 2001-12-06 Perseptive Biosystems, Inc. Conjugates of transporter peptides and nucleic acid analogs, and their use
US6258774B1 (en) * 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
KR20020081330A (ko) * 2000-02-16 2002-10-26 노오쓰웨스턴 유니버시티 폴리펩토이드 폐 계면활성제
IL137290A0 (en) 2000-07-13 2001-07-24 Asher Eldad Ben An electronic circuit for reducing the danger of exposure to radiation from a transmitter
JP3710368B2 (ja) 2000-09-25 2005-10-26 シャープ株式会社 積層フィルムの製造方法
US20020168354A1 (en) * 2000-11-10 2002-11-14 Daria Mochly-Rosen psiepsilonRack peptide composition and method for protection against tissue damage due to ischemia
US20030091640A1 (en) * 2001-02-08 2003-05-15 Srinivasan Ramanathan Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents
US20090075377A1 (en) * 2001-08-03 2009-03-19 Arbor Vita Corporation Molecular interactions in cells
CA2481979A1 (en) 2002-04-11 2003-10-16 Yasushi Taguchi Peptides chemically modified with polyethylene glycol
US6933275B2 (en) 2002-05-01 2005-08-23 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal
CA2506526C (en) * 2002-11-22 2017-04-18 Mang Yu Broad spectrum anti-viral therapeutics and prophylaxis
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
EP1597350B1 (en) 2003-02-27 2015-04-08 Yeda Research And Development Co., Ltd. Nucleic acid molecules, and compositions containing same useful for treating and detecting influenza virus infection
WO2004084805A2 (en) * 2003-03-19 2004-10-07 The J. David Gladstone Institutes Acetylated tat polypeptides and methods of use thereof
US7468418B2 (en) * 2003-04-29 2008-12-23 Avi Biopharma., Inc. Compositions for enhancing transport of molecules into cells
CA2549052A1 (en) * 2003-12-11 2005-06-30 The Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific antagonists of protein kinase c
EP1784483A2 (en) 2004-08-02 2007-05-16 The Board Of Trustees Of The Leland Stanford Junior University Peptide sequence for modulation of delta protein kinase c
US7265092B2 (en) * 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
JP4596391B2 (ja) 2005-02-10 2010-12-08 国立大学法人大阪大学 細胞透過性ペプチド
US7767642B2 (en) * 2005-04-15 2010-08-03 Arizona Biomedical Research Commission Therapeutic peptides for the treatment of metastatic cancer
CA2644089A1 (en) * 2005-09-19 2007-03-29 Kai Pharmaceuticals, Inc. Protein kinase c peptide modulators of angiogenesis
US7579318B2 (en) * 2005-12-06 2009-08-25 Centre De La Recherche De La Scientifique Cell penetrating peptides for intracellular delivery of molecules
US7741290B2 (en) * 2006-06-01 2010-06-22 The Board of Trustee of The Leland Stanford Juinior University Method of preventing progression of hypertension-induced heart failure with PKC peptides
WO2008042421A2 (en) * 2006-10-02 2008-04-10 The Board Of Trustees Of The Leland Stanford Junior University Peptides derived from the c2 domain of epsilon pkc, and use thereof
JP5645408B2 (ja) * 2006-11-16 2014-12-24 カイ ファーマシューティカルズ インコーポレーティッド 副甲状腺機能亢進症および高カルシウム血症性障害の治療のためのポリカチオン性カルシウムモジュレーターペプチド
CA2989778C (en) 2007-01-19 2020-06-30 Kai Pharmaceuticals, Inc. Method of modifying peptide compositions
KR20090117878A (ko) * 2007-01-19 2009-11-13 카이 파마슈티컬즈 통증의 완화를 위한 엡실론 억제제 화합물의 사용 방법

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002502376A (ja) * 1997-05-21 2002-01-22 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ 生物学的膜を横切る輸送を増強するための組成物および方法
JP2005500002A (ja) * 2000-10-02 2005-01-06 エリゼク・ファーマシュウティカルズ・インコーポレイテッド 生物学的に活性な薬剤を細胞関門を越えて輸送するための組成物および方法
US20020150984A1 (en) * 2001-01-18 2002-10-17 Daria Mochly-Rosen Peptides for activation and inhibition of deltaPKC
JP2004521108A (ja) * 2001-01-18 2004-07-15 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ δＰＫＣの活性化および阻害のためのペプチド
JP2005523326A (ja) * 2002-04-22 2005-08-04 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ プロテインキナーゼｃのペプチドインヒビター
JP2005527209A (ja) * 2002-04-22 2005-09-15 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 疼痛管理のためのプロテインキナーゼＣγのペプチドインヒビター
JP2006501165A (ja) * 2002-06-07 2006-01-12 ユニバーシティ オブ ローザンヌ Ｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤

Also Published As

Publication number Publication date
KR102274003B1 (ko) 2021-07-08
US20180371448A1 (en) 2018-12-27
CN108948144A (zh) 2018-12-07
CA2989778A1 (en) 2008-07-24
JP2021098725A (ja) 2021-07-01
KR20190140111A (ko) 2019-12-18
US20250034545A1 (en) 2025-01-30
EP3248985A1 (en) 2017-11-29
JP2025185093A (ja) 2025-12-18
WO2008089491A3 (en) 2008-11-27
EP2109619B1 (en) 2017-05-03
KR101775929B1 (ko) 2017-09-07
US20220282239A1 (en) 2022-09-08
KR20160005377A (ko) 2016-01-14
US20120178138A1 (en) 2012-07-12
AU2008206077A1 (en) 2008-07-24
US20090042769A1 (en) 2009-02-12
JP2016147905A (ja) 2016-08-18
EP2109619A4 (en) 2013-04-24
US9255124B2 (en) 2016-02-09
JP2018111717A (ja) 2018-07-19
EP2109619A2 (en) 2009-10-21
CN101675067A (zh) 2010-03-17
CN101675067B (zh) 2013-09-11
CA2989778C (en) 2020-06-30
CA2675665A1 (en) 2008-07-24
JP2023078424A (ja) 2023-06-06
CA2675665C (en) 2018-02-13
KR20090115852A (ko) 2009-11-09
JP5937643B2 (ja) 2016-06-22
US10077438B2 (en) 2018-09-18
WO2008089491A2 (en) 2008-07-24
US8067532B2 (en) 2011-11-29
US20160208237A1 (en) 2016-07-21
EP3248985B1 (en) 2019-10-23
JP2014224126A (ja) 2014-12-04
KR20170104634A (ko) 2017-09-15
US20200370032A1 (en) 2020-11-26
CN103524623A (zh) 2014-01-22

Similar Documents

Publication Publication Date Title
JP5937643B2 (ja) ペプチド組成物の安定性および送達効率を上昇させるための修飾方法
US20230158100A1 (en) Treatment of panx1 associates diseases
AU2008237138B2 (en) Methods of use of gamma inhibitor compounds for the attenuation of pain
CA3022763A1 (en) Novel peptides and peptidomimetics
Friis Peptide and protein derivatives

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130227

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130522

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130827

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131021

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140117

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140220

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140417

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140515

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140613

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140618

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20140925